Skip to main content
. 2017 Apr 11;18:152. doi: 10.1186/s12891-017-1514-4

Fig. 1.

Fig. 1

Persistence with oral bisphosphonates treatment by dosing frequency (a) and seropositive rheumatoid arthritis (b)